Company Overview

Phibro Animal Health Corporation (PAHC) is a global animal health and nutrition company focused on developing, manufacturing, and commercializing products that support the health, productivity, and food safety of livestock and poultry. The company operates primarily within the animal health, animal nutrition, and food safety industries, serving commercial producers, integrators, and distributors across protein production markets.

PAHC’s primary revenue drivers are its Animal Health and Mineral Nutrition businesses, which include medicated feed additives, nutritional specialty products, vaccines, and mineral-based feed ingredients. The company is positioned as a diversified supplier with a strong legacy in livestock-focused solutions and regulatory expertise. Phibro traces its origins to 1914 through its affiliation with Philipp Brothers and evolved into a standalone publicly traded animal health company following its initial public offering in 2014, as documented in SEC filings.

Business Operations

PAHC operates through two primary business segments: Animal Health and Mineral Nutrition. The Animal Health segment generates the majority of revenue and includes antibacterial products, vaccines, nutritional specialty products, and performance-enhancing products used in poultry, swine, cattle, and aquaculture production. The Mineral Nutrition segment focuses on trace minerals and mineral-based feed ingredients used in livestock and industrial applications.

The company maintains manufacturing, formulation, and distribution capabilities across multiple regions, supporting both domestic and international sales. PAHC controls proprietary formulations, regulatory approvals, and manufacturing assets that enable compliance across jurisdictions. Its operations include wholly owned subsidiaries and long-standing commercial partnerships with distributors and producers, particularly in regulated feed additive markets.

Strategic Position & Investments

Phibro’s strategic direction emphasizes disciplined growth through product innovation, geographic expansion, and selective acquisitions that enhance its animal health and nutrition portfolio. The company has invested in expanding its vaccine capabilities and nutritional specialty products, targeting higher-margin and differentiated offerings within protein production systems.

Notable strategic investments include the expansion of vaccine manufacturing capacity and the acquisition of Zoetis’ medicated feed additive portfolio in prior years, which strengthened Phibro’s market position in regulated antibacterial products. The company continues to invest in emerging areas such as alternatives to antibiotics, gut health solutions, and precision nutrition, as outlined in SEC filings and investor disclosures.

Geographic Footprint

PAHC is headquartered in the United States and operates globally across North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. The company maintains manufacturing and commercial operations in key livestock-producing regions, supporting a diversified international revenue base.

Its global footprint enables PAHC to serve multinational protein producers and adapt products to regional regulatory and market requirements. International markets represent a significant portion of revenue, with growing emphasis on expansion in emerging markets where protein consumption and commercial animal production continue to increase.

Leadership & Governance

Phibro is led by an executive team with long tenure in animal health, nutrition, and regulated industrial markets. The company emphasizes operational discipline, regulatory compliance, and long-term customer relationships as core elements of its leadership philosophy, as reflected in management commentary in SEC filings.

Key executives include:

• Jack C. Bendheim – Chairman of the Board, President, and Chief Executive Officer
• Richard L. Johnson – Executive Vice President and Chief Financial Officer
• Glenn Jones – Executive Vice President, Global Animal Health

Additional executive roles and governance details are disclosed in SEC filings; information beyond the executives listed above is data inconclusive based on available public sources.

Verification Requirements

All information presented is derived from publicly available disclosures including SEC filings, investor presentations, and coverage by major financial publications and market data providers. Where specific details could not be independently corroborated across multiple reputable sources, this has been explicitly noted as data inconclusive.